Panbela therapeutics announces us worldmeds nda approval for eflornithine (dfmo) in pediatric neuroblastoma

Minneapolis, dec. 18, 2023 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that us worldmeds® 1 (uswm), a kentucky-based specialty pharmaceutical company to whom it divested certain assets in its eflornithine pediatric neuroblastoma program, received fda approval of its new drug application (nda) for the use of eflornithine as a maintenance therapy for high-risk neuroblastoma patients who have achieved at least a partial response to certain prior therapies.
PBLA Ratings Summary
PBLA Quant Ranking